| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 07/31/2003 | US20030144495 Drosophila recombination-associated protein and methods for use |
| 07/31/2003 | US20030144492 Anticancer agents; central nervous system disorders; antiinflammatory agents |
| 07/31/2003 | US20030144491 Methods and materials relating to cadherin-like polypeptides and polynucleotides |
| 07/31/2003 | US20030144475 Human protein and cdna |
| 07/31/2003 | US20030144241 Antisense modulation of Smad6 expression |
| 07/31/2003 | US20030144239 Expression system |
| 07/31/2003 | US20030144236 Administering an enzyme inhibitor for treating tumor, abnormal cell growth and proliferation |
| 07/31/2003 | US20030144234 Administering a cathepsin modulator or enzyme inhibitor, select from a mRNA or a protein; gene expression inhibition, analgesics |
| 07/31/2003 | US20030144232 Expression system |
| 07/31/2003 | US20030144230 Covalent coupled of nucleic acids, peptides or proteins to active material for enhancing transfection efficiency; potentiation |
| 07/31/2003 | US20030144227 Pharmaceutical composition comprising Nit2 for use in inhibiting tumor cell growth |
| 07/31/2003 | US20030144226 Drug screening for an antiviral agent, viricides; genetic engineering |
| 07/31/2003 | US20030144222 Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof |
| 07/31/2003 | US20030144209 Bone anabolic agents for the treatment of bone disease |
| 07/31/2003 | US20030144205 Polynucleotide sequence encoding a polypeptide comprising an amino acid sequence that modulates protein degradation during gametogenesis and early development |
| 07/31/2003 | US20030144204 Expression vector with an inducible chimeric protein, wherein said protein comprises a mutant Akt polypeptide fused to a ligand binding domain |
| 07/31/2003 | US20030144200 Novel forms of the angiogenic factor vascular endothelial cell growth factor: VEGF |
| 07/31/2003 | US20030144198 Increasing gastrointestinal absorption |
| 07/31/2003 | US20030144194 Cancer treatment and prognosis |
| 07/31/2003 | US20030144180 Contains as active ingredient a therapeutically effective amount of agent for either enhancing protein kinase c production and/or activation |
| 07/31/2003 | US20030144176 Methods and compositions relating to MEK5 and cardiac hypertrophy and dilated cardiomyopathy |
| 07/31/2003 | US20030143735 Contacting human vpr interacting protein with a test compound and comparing the affinity of the vpr in the presence and absence of it |
| 07/31/2003 | US20030143732 RNA interference mediated inhibition of adenosine A1 receptor (ADORA1) gene expression using short interfering RNA |
| 07/31/2003 | US20030143730 The viral DNA is introduced into a culture of encapsidation cells and the viruses produced are harvested following release into the supernatant such as by ultrafiltration; use of iodixanol for purification of adenoviruses |
| 07/31/2003 | US20030143702 Vesicular monoamine transporter gene therapy in parkinson's disease |
| 07/31/2003 | US20030143696 Human chemokine beta-13 |
| 07/31/2003 | US20030143693 Growing, under suitable conditions, procaryotic or eucaryotic host cells transformed or transfected with a specific DNA, and isolating the desired polypeptide product of the expression of such DNA sequence |
| 07/31/2003 | US20030143686 Transferases |
| 07/31/2003 | US20030143676 Receptor polypeptides and polynucleotides encoding such polypeptides; for treating a disorder characterized by an elevated level of osteopontin |
| 07/31/2003 | US20030143675 Novel 38594, 57312, 53659, 57250, 63760, 49938, 32146, 57259, 67118, 67067, 62092, 8099, 46455, 54414, 53763, 67076, 67102, 44181, 67084FL, 67084ALT, FBH58295FL, 57255, and 57255alt molecules and uses therefor |
| 07/31/2003 | US20030143672 Providing conservative or semi-conservative amino acid substitutions at positions 3 and/or 5 and/or 7 of these epitopes, useful in eliciting immune responses with respect to corresponding wildtype epitopes |
| 07/31/2003 | US20030143667 Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions |
| 07/31/2003 | US20030143656 Drug screening compounds which inhibit rate of phosphorylation by kinase having hydrophobic pocket domain; surface plasmon resonance; fusion proteins; anticancer-/ antidiabetic agents |
| 07/31/2003 | US20030143626 Such as cyclin-dependent kinases and/or bax genes/proteins covalently linked to platform compound (thioredoxin); drug screening |
| 07/31/2003 | US20030143621 Contacting a cellular component with a reagent which binds to PC-1 (prostate cancer-1) protein |
| 07/31/2003 | US20030143620 Carbohydrate ligands specific for MHC molecules |
| 07/31/2003 | US20030143595 Isolated and/or recombinantly produced polypeptide; use in regulating spermatogenesis, cell differentiation and proliferation |
| 07/31/2003 | US20030143266 Combining cationic lipid with polyethyleneglycol derivative to produce homogeneous micellar lipids; combining with biologically active molecule to form micellar complexes |
| 07/31/2003 | US20030143248 Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
| 07/31/2003 | US20030143238 Vaccine compositions and methods useful in inducing immune protection against arthritogenic peptides involved in the pathogenesis of rheumatoid arthritis |
| 07/31/2003 | US20030143232 Incubating survivin and p34cdc2-cyclin B1 kinase complex in presence of an agent; determining whether agent modulates phosphorylation of survivin by p34cdc2-cyclin B1 kinase complex, identifying an agent which modulates phosphorylation |
| 07/31/2003 | US20030143231 Assaying the ability of the compound to modulate 57749 nucleic acid expression or 57749 polypeptide activity, thereby identifying a compound capable of treating a pain disorder |
| 07/31/2003 | US20030143227 For therapy of leukemia and lymphoblastoma, may also be used as imaging agents and diagnostic agents for detecting expression levels of the protein |
| 07/31/2003 | US20030143223 Modulating the activity of one or more elements in the complement/lipid pathway |
| 07/31/2003 | US20030143217 For therapy of smooth muscle cell hyperplasia; cancer therapy |
| 07/31/2003 | US20030143212 Corneal cells expressing active agents and methods of use thereof |
| 07/31/2003 | US20030143209 For gene therapy of cancers or cardiovascular conditions |
| 07/31/2003 | US20030143206 Increasing the level of at least one isoform of the enzyme nitric oxide synthase in the cells of the ano-rectal region for therapy of anal disease |
| 07/31/2003 | US20030143204 Making the inhibitor consisting of an RNA function inhibiting sequence that is specific to expressible nucleic acid sequence in mammal; inserting the inhibitor into a vessel in the mammal; delivering function inhibiting sequence to a cell |
| 07/31/2003 | US20030143203 Tumor therapy |
| 07/31/2003 | US20030143202 Anemia |
| 07/31/2003 | US20030143200 Porcine adenovirus E1 region |
| 07/31/2003 | US20030143196 To regulate an immune response in an animal |
| 07/31/2003 | CA2510751A1 Multimers of receptor-binding ligands |
| 07/31/2003 | CA2476773A1 Monoclonal antibodies against extracellular loops of c5ar |
| 07/31/2003 | CA2473944A1 Methods and compositions for rna interference |
| 07/31/2003 | CA2473906A1 Cooperative oligonucleotides |
| 07/31/2003 | CA2473829A1 Use of tgf-.beta. antagonists to treat or to prevent chronic transplant rejection |
| 07/31/2003 | CA2473741A1 A method for generating engineered cells for locus specific gene regulation and analysis |
| 07/31/2003 | CA2473717A1 Dna dosage forms |
| 07/31/2003 | CA2473474A1 Alteration of rab38 function to modulate mammalian pigmentation |
| 07/31/2003 | CA2472729A1 Nuclear-envelope and nuclear-lamina binding chimeras for modulating gene expression |
| 07/31/2003 | CA2472333A1 Ex-vivo gene therapy of diabetes using iap polypeptides |
| 07/31/2003 | CA2469721A1 Stabilized formulations of adenovirus |
| 07/31/2003 | CA2469685A1 Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| 07/30/2003 | EP1331270A1 Novel recombinant feline herpesvirus 1 and polyvalent vaccine with the use of the same |
| 07/30/2003 | EP1331269A1 Novel protein, process for producing the same and use thereof |
| 07/30/2003 | EP1331268A1 Novel proteins, genes encoding them and method of using the same |
| 07/30/2003 | EP1330548A2 Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries |
| 07/30/2003 | EP1330543A2 Nucleic acid sequences differentially expressed in cancer tissue |
| 07/30/2003 | EP1330538A2 Cd36 as a heat shock protein receptor and uses thereof |
| 07/30/2003 | EP1330531A2 Influenza virus vector for infection of dendritic cells |
| 07/30/2003 | EP1330528A2 Regulation of human serine-threonine protein kinase |
| 07/30/2003 | EP1330520A2 Therapeutic oligonucleotides of reduced toxicity |
| 07/30/2003 | EP1330516A2 Surface transfection and expression procedure |
| 07/30/2003 | EP1330515A1 Methods of agonizing and antagonizing fabk |
| 07/30/2003 | EP1330469A2 Glycoproteins and methods of use therefof |
| 07/30/2003 | EP1330265A1 Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids |
| 07/30/2003 | EP1330263A2 Method for down-regulating ige |
| 07/30/2003 | EP1330252A1 In vivo stimulation of angiogenic activity |
| 07/30/2003 | EP1330240A2 Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular diseases |
| 07/30/2003 | EP1330156A1 Modulating cytokine or hormone signalling in an animal comprising up-regulating the expression of socs sequence in the animal |
| 07/30/2003 | EP0916074B1 Magnetic rotation sensor |
| 07/30/2003 | EP0906124B1 Device and method for encapsulated gene therapy |
| 07/30/2003 | EP0859628B1 Drug, in particular for modulating the immunological response for the control of viruses, tumours, bacteria and parasites |
| 07/30/2003 | EP0783482B1 Cationic transport reagents |
| 07/30/2003 | CN1433478A Novel colloid synthetic vectors for gene therapy |
| 07/30/2003 | CN1433477A Method of achieving persistent transgene expression |
| 07/30/2003 | CN1433471A 85Kgda neisserial antigen |
| 07/30/2003 | CN1433470A Neisserial antigenic peptides |
| 07/30/2003 | CN1433469A Therapeutically useful synthetic oligonucleotides |
| 07/30/2003 | CN1433466A MASP-3, complement-fixing enzyme, and uses for it |
| 07/30/2003 | CN1433325A Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| 07/30/2003 | CN1433318A Vascular endothelial growth factor-2 |
| 07/30/2003 | CN1432645A Human cell bank and its application in autogenous cell transplantation and tissue repair |
| 07/30/2003 | CN1432411A New use of gens mutant of human telomerase inverse transcriptase-like component |
| 07/29/2003 | US6600087 Propagation of cattle embryo; obtain fetal tissue, extract nucleus, transfer nucleus to oocyte, activate cytoplasm complex, propagate cells, implant cells into cattle, allow fetus to propagate |
| 07/29/2003 | US6600030 Nucleotide sequences which code binding protein for use in diagnosis and treatment of asthma, arthritis, Crohn's and Grave's diseases and cystic fibrosis |
| 07/29/2003 | US6600027 Polynucleotide molecules encoding neospora proteins |
| 07/29/2003 | US6600024 Polypeptide for use in the treatment and prevention of cell proliferative disorders |